Clinical-stage biopharma company Mersana Therapeutics unveiled a global collaboration with GlaxoSmithKline Monday that gives the industry behemoth the exclusive option to co-develop and commercialize Mersana’s antibody-drug conjugate (ADC) XMT-2056.
https://www.pharmalive.com/wp-content/uploads/2022/04/BioSpaceGSK4-27-2022.jpg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-08-09 10:01:122022-08-09 10:43:27GSK ups ante in ADC discovery game with $1.4B Mersana option deal
